Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients
- 5 August 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 70 (4), 513-522
- https://doi.org/10.1007/s00280-012-1940-9
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myelomaLeukemia & Lymphoma, 2012
- Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitorCancer Chemotherapy and Pharmacology, 2011
- A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumorsInvestigational New Drugs, 2011
- Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin LymphomaBritish Journal of Haematology, 2009
- Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challengesCancer Letters, 2009
- Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumorsFuture Oncology, 2009
- Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemiaBlood, 2008
- Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell LymphomaClinical Cancer Research, 2008
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- Determination of mean valproic acid serum level by assay of a single pooled sampleClinical Pharmacology & Therapeutics, 1981